ATXN3 and malignant colon neoplasm: Given that ATXN3 modulates tumoral PD-L1 expression to evade antitumor immunosurveillance, we opted to utilize a xenograft colon cancer model to examine the impact of ATXN3 on cancer growth in immune-compromised mice.